Certain residues in J5, the best known MBP(85–99) antagonist, were replaced with their homo-β-counterparts to obtain antagonists with far superior stability and antagonistic activities, features that eventually translated into 1.5 to 2 fold enhancement of therapeutic efficacy in experimental models of MS. The gene discussed is MBP; the disease is myeloid sarcoma.